USFDA successfully closes inspection at Torrent Pharma Gujarat facility
Ahmedabad: Torrent Pharma has announced that the US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (“EIR”) for the Company’s Oral-Oncology manufacturing facility situated in Bileshwarpura, Gujarat. The inspection has now been successfully closed by the USFDA.
Medical Dialogues team had earlier reported that the USFDA had concluded the Pre-Approval Inspection (PAI) inspection with 5 procedural observations at the said facility.
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC).
Read also: Torrent Pharma reports 52 percent increase in profit after tax to Rs 443 crore for Q3
Next Story
